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Introduction Atazanavir (ATV), also known as Reyataz, is a protease inhibitor (PI) used for the treatment of the human immunodeficiency virus (HIV) infection (Swainston Harrison and Scott, 2005; Croom et al., 2009) . ATV was approved by the U.S. Food and Drug Administration (FDA) in 2003 and is used in combination with other antiretroviral agents, such as ritonavir (RTV). The FDA recently also approved the use of ATV without cotreatment with RTV in selective PI-naïve patients. The recommended dosage for treatment-naïve patients is 300 mg of ATV with 100 mg of RTV once daily. ATV can be taken in a dose of 400 mg once daily without RTV for selected PI-naïve patients who cannot tolerate RTV (Rivas et al., 2009) . ATV has particular advantages over other PIs because of its moderate resistance profile, minimal effect on lipid profiles, low capsule burden, and once-daily dosing (Rivas et al., 2009 ).
Despite these advantages, ATV is associated with various adverse drug reactions (Busti et al., 2004; Havlir and O'Marro, 2004) . Nausea was reported in ~35% of the patients receiving ATV, followed by abdominal pain, headache and diarrhea (Goldsmith and Perry, 2003) . The most common laboratory abnormality is hyperbilirubinemia, which was reported in ~40% of patients who received ATV 400 mg once daily. ATV-induced hyperbilirubinemia rarely led to discontinuation of treatment; however, ~8% of patients developed clinical jaundice (Goldsmith and Perry, 2003; Sulkowski, 2004) . In addition, elevation of alanine aminotransferase and aspartate aminotransferase activity was noted in ~14% of the patients receiving ATV, and was unrelated to bilirubin levels (Goldsmith and Perry, 2003) . Monitoring liver function is recommended for ATV-treated patients, especially for the patients with existing liver diseases (Eholie et al., 2004) . The exact mechanisms of ATV-related adverse effects are unknown.
It is generally accepted that a predominant pathway of drug-induced toxicity is via the generation of reactive metabolites (Baillie, 2006; Guengerich and MacDonald, 2007) .
The reactive metabolites, such as aldehyde, epoxide, quinone methide, and hydroxylamine, can cause various adverse side effects (O'Brien et al., 2005; Tang and Lu, 2010) . For instance, felbamate, a broad spectrum antiepileptic, resulted in hepatotoxicity by way of its metabolite atropaldehyde (Dieckhaus et al., 2002) . Until now, limited information has been available on ATV metabolism. In 2009, five ATV metabolites were reported, which included one N-dealkylation product, two metabolites resulting from carbamate hydrolysis, one hydroxylated product, and one keto-metabolite (ter Heine et al., 2009) . Reactive metabolites of ATV have not been identified.
In the current study, we used a metabolomic approach, which has been proved to be a powerful tool in studying drug metabolism (Chen et al., 2006; Li et al., 2010) , to investigate the metabolism of ATV in mice and human liver microsomes (HLM). We identified five known and thirteen novel ATV metabolites. Three potential reactive metabolites were detected and characterized: one aromatic aldehyde, one alphahydroxyaldehyde, and one hydrazine. CYP3A4 was identified as the primary enzyme This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Chemicals and Reagents
ATV (methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3, 3- dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl) methyl]hydrazinyl]- 3,3-dimethyl-1-oxobutan-2-yl
Animals and Treatments
All mice (two to four months old) were maintained under a standard 12-hour dark and 12-hour light cycle with water and chow provided ad libitum. Handling was in accordance with study protocols approved by the University of Kansas Medical Center
Institutional Animal Care and Use Committee. The mice were treated (po) with ATV (50 mg/kg) or 4-(pyridin-2-yl)-benzaldehyde (12 mg/kg) and housed separately in metabolic cages for 18 hours. Urine and feces were collected for metabolite analysis. Briefly, urinary samples were prepared by mixing 40 µl of urine with 160 µl of 50% acetonitrile and were centrifuged at 20,000 relative centrifugal forces (rcf) for 10 min. All the incubations were performed in duplicate.
Biomarkers of Metabolic Activation
Because most reactive metabolites are not stable, it is difficult to detect them directly.
Reactive intermediates can form adducts with trapping agents, such as glutathione between aldehyde metabolites and lysine residues on proteins (Evans et al., 2004) .
UPLC-TOFMS can be used to detect adducts of reactive metabolites and the trapping agents. In the current study, methoxylamine, semicarbazide, and INH were used as trapping agents.
Synthesis and Characterization of Methyl Oxime of 4-(Pyridin-2-yl)benzaldehyde
Methoxylamine hydrochloride (172 mg, 2.1 mmol) and pyridine (167 mg, 2.1 mmol)
were added to a solution of 4-(pyridin-2-yl)benzaldehyde (366 mg, 2.0 mmol) in MeOH 
UPLC-TOFMS Analysis
ATV and its metabolites were separated using a 100 mm x 2.1 mm (Acquity 1.7 µm)
UPLC BEH C-18 column (Waters, Milford, MA). The flow rate of the mobile phase was 0.3 ml/min with a gradient ranging from 2% to 98% aqueous acetonitrile containing 0.1%
formic acid in a 10-min run. TOFMS was operated in both positive and negative modes with electrospray ionization. The source temperature and desolvation temperature were set at 120 °C and 350 °C, respectively. Nitrogen was applied as the cone gas (10 L/hour), and desolvation gas (700 L/hour). Argon was applied as the collision gas. TOFMS was 
Identification of an Aromatic Aldehyde (m1) in ATV Metabolism
A dealkylated ATV metabolite (M1) was reported in a previous study (ter Heine et al., 2009) . Theoretically, an aldehyde should be generated together with the formation of and 4). In the ATV-treated mouse urines, the dealkylated ATV metabolite (M1) was detected, but the expected aldehyde (m1) was not found. However, the further metabolites of m1 were detected, which included an acid (m2), a glycine-conjugate product (m3), and an N-acetylcysteine-conjugate product (m5) (Figure 3 ). In addition, the existence of m1 was confirmed in incubations with HLM using methoxylamine as a trapping agent. The evidence for m1 formation is summarized in Figure 4 . The chromatograms of M1, m2, m3, and m5 are presented in Figure 4A . M1 was eluted at Figure 4D ). In addition, m2 was confirmed by comparison of retention time and accurate mass with an authentic standard sample. Figure 4E .
2-(4-(pyridin-2-yl)benzamido)acetic acid (m3
The ion at m/z 211 was formed by loss of the HCOOH moiety. Figure 4F . Metabolite m5 was observed in both ATV and 4-(pyridin-2-yl)benzaldehyde (m1) treated mouse urines.
2-acetamido-3-(4-(pyridin-2-yl)benzylthio)propanoic acid (m5
4-(pyridin-2-yl)benzaldehyde (m1).
In the incubation with HLM and ATV, 4-(pyridin-2-yl)benzaldehyde (m1) was trapped using methoxylamine. The formed oxime was eluted Figure 4H ). The structure of m1-oxime was confirmed by comparing the retention time and accurate mass with the synthetic authentic standard sample, which was characterized by NMR.
Identification of an Alpha-Hydroxyaldehyde (M15') in ATV Metabolism
In ATV-treated mouse urines and in vitro study using HLM, a novel dealkylated metabolite (M15) of ATV was identified. Meanwhile, an alpha-hydroxyaldehyde (M15') was trapped by INH ( Figure 5 ) and semicarbazide (data not shown) in the incubation of ATV in HLM. The formations of M15 and M15' were NADPH dependent ( Figure 5A ). Figure 5C ).
Identification of a Hydrazine (M16) in ATV Metabolism
In the incubation with ATV and HLM, a hydrazine (M16), resulting from the dealkylation and hydrolysis, was identified ( Figure 6 ). The formations of M16 were NADPH dependent ( Figure 6A) Figure   6B ).
ATV Metabolism in HLM
Fourteen ATV metabolites were identified in the incubation with HLM (Supplemental Figure 7A . M2 is the most abundant metabolite of ATV in the incubation with HLM, followed by M15 and M1. The metabolic pathways of M1 and M15 should be emphasized because (1) they are major metabolic pathways in ATV metabolism; (2) two aldehydes (m1 and M15') are generated simultaneously with the formation of metabolites M1 and M15; and (3) the generation of the hydrazine (M16) is also dependent on M1.
Role of P450s in ATV Metabolism
The incubation of ATV with nine different human cDNA-expressed P450s (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP3A4) revealed that CYP3A4 is the primary enzyme contributing to ATV metabolism (Supplemental Table 1 ). CYP3A4 and CYP2D6 co-contributed to the metabolic pathway of metabolite M1, but CYP3A4 was more important than CYP2D6 (Supplemental Table 1 ). CYP3A4 was the dominant enzyme responsible for the formation of metabolite M15 ( Figures 7B and 7C ). The inhibitory effect on the M1 and M15 metabolic pathways was further verified by coincubation of KCZ with HLM and cDNA-expressed CYP3A4. In the incubation with HLM, the formations of M1 and M15 were suppressed up to 90% by KCZ at 10 µM ( Figure 7B ). In the incubation with CYP3A4, KCZ at 10 µM inhibited the formations of M1 to 95% and M15 to 90% ( Figure 7C ). one aromatic aldehyde (m1), one alpha-hydroxyaldehyde (M15'), and one hydrazine (M16), were detected and characterized for the first time. The levels of the two aldehydes (m1 and M15') were high because they were generated from two primary metabolic pathways of ATV, M1 and M15 (Figures 2 and 7A ).
The aromatic aldehyde (m1) that we identified in ATV metabolism (Figures 3 and 4) was further oxidized to the corresponding acid m2, and then conjugated with glycine to yield the metabolite m3. This pathway may contribute to the detoxication of aldehyde m1. On the other hand, an N-acetylcysteine-conjugate product (m5) was detected in the ATVtreated mouse urines. The formation of metabolite m5 indicates that the further metabolite of m1 can interact and form adduct with GSH (m4) (Figure 3 ). The exact mechanism of m5 formation was not determined in the current study. Based upon a previous report (Ji et al., 2007) , an intermediate sulfate is proposed. Briefly, m1 can be reduced to an alcohol, and subsequently sulfated to form a sulfate that serves as a leaving group. The resulting sulfate reacts with GSH to form m4, which is further metabolized to an N-acetylcysteine-conjugate product (m5). Clarification of the mechanism of this interaction with GSH and its implication in ATV-related adverse effects is desired in future studies.
This article has not been copyedited and formatted. The final version may differ from this version. The hydrazine (M16) that we identified is a further metabolite of M1. It has been reported that hydrazine can cause hepatic lesions and neurotoxicity (Waterfield et al., 1993; Nicholls et al., 2001) . In summary, we identified three potential reactive metabolites of ATV, which included two aldehydes and one hydrazine. CYP3A4 was determined to be the primary enzyme contributing to the formation of these aldehydes and hydrazine. Further studies are suggested to illustrate the role of these potential reactive metabolites in ATV-related adverse effects.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 3 . A scheme of m1 formation and its further metabolism. m1 was generated from ATV spontaneously with M1, and it was trapped using methoxylamine (MeONH 2 ).
In mice, m1 can be further metabolized to acid (m2) and conjugated with glycine (m3).
m1 may interact with GSH (m4) and be further metabolized to an N-acetylcysteineconjugate product (m5). 
